Brokers Set Expectations for X4 Pharmaceuticals, Inc.’s FY2025 Earnings (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Stock analysts at B. Riley issued their FY2025 earnings estimates for X4 Pharmaceuticals in a research report issued on Wednesday, August 30th. B. Riley analyst K. Patel forecasts that the company will post earnings per share of ($0.53) for the year. B. Riley has a “Buy” rating on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.80) per share. B. Riley also issued estimates for X4 Pharmaceuticals’ FY2026 earnings at ($0.48) EPS.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings results on Thursday, August 10th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.16). During the same quarter in the prior year, the company posted ($0.60) earnings per share.

Other equities research analysts have also recently issued research reports about the stock. Stifel Nicolaus upped their price objective on shares of X4 Pharmaceuticals from $4.00 to $5.00 in a report on Wednesday, May 17th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of X4 Pharmaceuticals in a research report on Friday, August 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $3.50.

X4 Pharmaceuticals Stock Performance

Shares of XFOR stock opened at $1.30 on Thursday. The company’s fifty day moving average price is $1.62 and its 200-day moving average price is $1.49. The stock has a market cap of $213.76 million, a PE ratio of -1.25 and a beta of 0.69. The company has a current ratio of 6.64, a quick ratio of 6.64 and a debt-to-equity ratio of 0.47. X4 Pharmaceuticals has a 12 month low of $0.65 and a 12 month high of $2.58.

Insider Transactions at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, insider Murray Stewart sold 130,056 shares of X4 Pharmaceuticals stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $1.06, for a total value of $137,859.36. Following the completion of the sale, the insider now owns 146,504 shares of the company’s stock, valued at approximately $155,294.24. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, Director Michael S. Wyzga acquired 25,000 shares of the stock in a transaction that occurred on Friday, August 18th. The shares were bought at an average price of $1.20 per share, for a total transaction of $30,000.00. Following the completion of the transaction, the director now directly owns 76,667 shares in the company, valued at $92,000.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Murray Stewart sold 130,056 shares of X4 Pharmaceuticals stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $1.06, for a total transaction of $137,859.36. Following the completion of the sale, the insider now directly owns 146,504 shares of the company’s stock, valued at approximately $155,294.24. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 159,157 shares of company stock worth $197,678. Corporate insiders own 1.08% of the company’s stock.

Hedge Funds Weigh In On X4 Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of XFOR. Bain Capital Life Sciences Investors LLC increased its position in X4 Pharmaceuticals by 30.8% during the second quarter. Bain Capital Life Sciences Investors LLC now owns 15,960,588 shares of the company’s stock valued at $30,964,000 after acquiring an additional 3,758,078 shares during the last quarter. NEA Management Company LLC grew its stake in shares of X4 Pharmaceuticals by 79.9% during the 4th quarter. NEA Management Company LLC now owns 11,736,793 shares of the company’s stock valued at $11,655,000 after purchasing an additional 5,213,636 shares during the period. BlackRock Inc. increased its position in shares of X4 Pharmaceuticals by 2,547.2% during the 2nd quarter. BlackRock Inc. now owns 9,095,274 shares of the company’s stock valued at $17,645,000 after purchasing an additional 8,751,694 shares during the last quarter. Polar Capital Holdings Plc bought a new position in shares of X4 Pharmaceuticals in the 2nd quarter worth approximately $9,700,000. Finally, Stonepine Capital Management LLC bought a new position in shares of X4 Pharmaceuticals in the 2nd quarter worth approximately $8,934,000. 78.50% of the stock is owned by institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia.